Full Breakdown
Sam Neill Declares Cancer-Free Status After CAR T-Cell Therapy
4/29/2026, 8:49:08 PM
Cancer-Free Announcement
In a live interview with Australian broadcaster 7News, 78-year-old actor Sam Neill confirmed that recent scans show no detectable cancer, calling the result “extraordinary” and expressing readiness to resume acting.
Diagnosis and Treatment Journey
Neill first revealed a diagnosis of angioimmunoblastic T-cell lymphoma (AITL), a stage-III blood cancer, in 2023 after swollen glands were noted during promotion of *Jurassic World Dominion* in 2022. He underwent chemotherapy, which he described as “pretty miserable business,” but the regimen eventually stopped working, leaving him “at a loss and it looked like I was on the way out.” He then entered an Australian CAR-T clinical trial.
CAR T-Cell Therapy: Mechanism, Approvals, and Cost
CAR T-cell therapy extracts a patient’s T cells, genetically engineers them to target lymphoma cells, and reinfuses the modified cells as a living drug. In Australia the approach remains limited to clinical-trial participants and a narrow list of cancers covered by the public health system; privately it can exceed A$600,000 per patient (?£320,000, US$430,000). In the United States the FDA has approved six CAR-T products for blood cancers such as acute lymphoblastic leukemia, mantle-cell lymphoma, various B-cell lymphomas, diffuse large B-cell lymphoma and multiple myeloma.
Official Statements & Responses
Neill told 7News that the scan result “is an extraordinary thing,” expressed excitement about returning to film, and urged Australian state and federal governments to broaden CAR-T availability. The Snowdome Foundation echoed his appeal, calling for nationwide subsidised access.
Criticism & Opposition
Critics note that CAR-T therapy remains very high—over A$600,000 per patient privately—and is confined to clinical-trial participants in Australia, with public funding limited to a narrow list of blood cancers. The cost disparity compared with publicly subsidised treatments fuels calls for policy reform to prevent inequitable access.
Conflicting Reports & Gaps
Cost figures differ by region—A$600,000 in Australia, £280,000 in the UK, US$430,000 in the United States—reflecting disparate health-system pricing. Long-term outcomes for solid-tumour CAR-T use remain uncertain.
Verbatim Quotes
- “I’ve just had a scan just now and there is no cancer in my body, that’s an extraordinary thing.” — Sam Neill, Actor
- “I’m very, very excited that this can happen.” — Sam Neill, Actor
- “I’m not afraid to die, but it would annoy me.” — Sam Neill, Actor
- “I was at a loss and it looked like I was on the way out, which wasn’t ideal obviously.” — Sam Neill, Actor
What’s Next
Neill plans to resume film work while continuing his campaign with Snowdome to secure nationwide, subsidised CAR-T access for Australian patients, positioning his case as a high-profile example of immunotherapy’s promise.
